Literature DB >> 10926054

New strategies for treating chronic depression.

J H Kocsis1.   

Abstract

This article provides an update on the diagnosis of chronic depression subtypes, the clinical and public health significance of chronic depression, and a review of what is known about its treatment. The efficacy of antidepressant medications for pure dysthymia and double depression has been established, yet fewer than 50% of patients have achieved full remission with a single agent. Traditional antidepressant psychotherapies appear to have limited effectiveness for chronic depression. In one recent study, a combination of cognitive behavioral analysis system of psychotherapy and a newer antidepressant, nefazodone, yielded the highest response and remission rates ever reported in this population (73% response rate, 48% remission rate in an intent-to-treat sample). This combination merits further study for treatment of chronic depression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10926054

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  3 in total

1.  The state of knowledge of chronic depression.

Authors:  Alan J Gelenberg; James H Kocsis; James P McCullough; Philip T Ninan; Michael E Thase
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

2.  Predictors of major depression six months after admission for outpatient treatment.

Authors:  Mark I Weinberger; Jo Anne Sirey; Martha L Bruce; Moonseong Heo; Eros Papademetriou; Barnett S Meyers
Journal:  Psychiatr Serv       Date:  2008-10       Impact factor: 4.157

3.  Exploring venlafaxine pharmacokinetic variability with a phenotyping approach, a multicentric french-swiss study (MARVEL study).

Authors:  Célia Lloret-Linares; Youssef Daali; Sylvie Chevret; Isabelle Nieto; Fanny Molière; Philippe Courtet; Florence Galtier; Raphaëlle-Marie Richieri; Sophie Morange; Pierre-Michel Llorca; Wissam El-Hage; Thomas Desmidt; Frédéric Haesebaert; Philippe Vignaud; Jerôme Holtzmann; Jean-Luc Cracowski; Marion Leboyer; Antoine Yrondi; Fabienne Calvas; Liova Yon; Philippe Le Corvoisier; Olivier Doumy; Kyle Heron; Damien Montange; Siamak Davani; Julien Déglon; Marie Besson; Jules Desmeules; Emmanuel Haffen; Frank Bellivier
Journal:  BMC Pharmacol Toxicol       Date:  2017-11-07       Impact factor: 2.483

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.